A Phase 3 interventional study of Dexmedetomidine infusion and Postoperative matched placebo of 0.9% saline infusion in Bowel Diseases, Inflammatory, Bowel Surgery and Laparoscopic Abdominal Surgeries, sponsored by Dr. Naveed Siddiqui. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-24.
Sponsored by Dr. Naveed Siddiqui · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 156 studies in Inflammatory Bowel Diseases with a site in Canada — 35 open to participants now, 50 under way, 6 of them phase 3. Inflammatory Bowel Diseases · Canada.
Among the 156 studies in Inflammatory Bowel Diseases with a site in Canada, this one is the 77th largest by planned enrollment of the 119 interventional ones that give a count, is one of 9 that started in 2026, is one of 24 in phase 3, reaches primary completion later than 25 of the 49 other live ones, and was the 152nd registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →35 of the 156 studies in Inflammatory Bowel Diseases with a site in Canada are open now. Recruiting first, the newest first:
Palisade Bio · Sites in Canada, United States, Czechia and 9 more countries
Ages 18–75
Eli Lilly and Company · Sites in Canada, United States, Denmark and 4 more countries
Ages 3 wk+ · Women only
University of British Columbia · Sites in Canada
Ages 9–17
University of British Columbia · Sites in Canada
Ages 19+ · Women only · Healthy volunteers
University of Alberta · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
156 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 33 · Phase 3 28 · Phase 4 10
First in 2002; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is close to the median of 68 across 875 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 120 across the 119 interventional studies, 157 across the 36 observational. Of the 91 that completed or were terminated, 32 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 156 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Dr. Naveed Siddiqui as lead sponsor.
Dr. Naveed Siddiqui has 1 study filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
14 of the studies in Inflammatory Bowel Diseases with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07434310Phase 3Dr. Naveed SiddiquiUse of Dexmedetomidine to Improve Pain Control and Recovery After Laparocopic-Assisted Bowel Surgery in Adults | 2027-07-01 |
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT07814274University of British ColumbiaProspective Intestinal Ultrasound Study for Artificial Intelligence Algorithm Development | 2027-02-01 |
| NCT05722236Jennifer JonesIBD Strong Peer2Peer for Self-Management of Psychological Distress | 2027-03 |
| NCT06548399McMaster UniversityLongitudinal Study on Bacterial Production of LPC and LPA in Patients With Inflammatory Bowel Disease | 2027-03-30 |
Add all 14 to your calendar (.ics) → With an account.
Among the 156 studies in Inflammatory Bowel Diseases with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is testing whether continuing a medication called dexmedetomidine after surgery can improve quality of recovery for adults undergoing laparoscopic-assisted bowel surgery.
After bowel surgery, many patients experience significant pain and slow recovery. Pain is often treated with strong opioid medications, which can cause side effects such as nausea, vomiting, constipation, sedation, and delayed return of bowel function. Other pain control options, such as epidurals or nerve blocks, are not always suitable for laparoscopic bowel surgery and may have their own risks or limitations. As a result, there are few effective non-opioid options for managing pain in this patient group.
Dexmedetomidine is a medication that can reduce pain and the need for opioids while providing sedation without affecting breathing. It is commonly used during surgery, but it is not known whether continuing dexmedetomidine after surgery improves pain control and overall recovery in bowel surgery patients. This study aims to answer that question.
The PODEX study is a single-centre, randomized, double-blind, placebo-controlled trial. Adults aged 18 to 70 years who are having elective or semi-elective laparoscopic-assisted bowel surgery will be invited to take part. About 94 participants will be enrolled. After surgery, participants will be randomly assigned (by chance) to receive either a continuous dexmedetomidine infusion or a placebo (salt water) infusion for 48 hours. Neither the participants nor the study team will know which treatment a participant receives during the study. All participants will receive the same standard surgical care, anesthesia, and postoperative pain medications.
The main outcome of the study is quality of recovery, measured 48 hours after surgery using a short questionnaire (QoR-15) that asks about comfort, pain, physical well-being, and emotional state. Other outcomes include recovery scores at additional time points, pain levels, opioid use, nausea and vomiting, return of bowel function, length of hospital stay, and side effects such as low blood pressure or slow heart rate.
The results of this study may help determine whether postoperative dexmedetomidine is a safe and effective way to improve recovery and reduce opioid use after bowel surgery.
Postoperative pain control and recovery following bowel surgery remain significant clinical challenges. Although laparoscopic-assisted techniques have reduced surgical trauma compared with open procedures, many patients still experience substantial postoperative pain, delayed return of bowel function, opioid-related adverse effects, and prolonged hospitalization. These factors negatively affect patient-centered recovery outcomes and increase healthcare utilization.
Opioids remain a central component of postoperative analgesia after bowel surgery. However, opioid-based pain management is associated with well-recognized adverse effects, including nausea, vomiting, ileus, sedation, pruritus, respiratory depression, and the risk of persistent opioid use. In patients undergoing bowel surgery, these adverse effects are particularly problematic because impaired gastrointestinal motility can delay recovery and discharge. While multimodal analgesia strategies aim to reduce opioid exposure, commonly used alternatives such as nonsteroidal anti-inflammatory drugs (NSAIDs) are often contraindicated in this population, and regional anesthesia techniques (e.g., epidural analgesia or transversus abdominis plane blocks) are technically demanding, resource intensive, and not routinely used for laparoscopic-assisted procedures.
Dexmedetomidine is a selective α2-adrenergic receptor agonist with analgesic, sedative, and sympatholytic properties. Its mechanism of action includes modulation of nociceptive signaling in the spinal cord and central nervous system, reduction of sympathetic outflow, and attenuation of stress responses without clinically significant respiratory depression. Intraoperative dexmedetomidine has been shown to reduce postoperative pain scores, decrease opioid requirements, improve hemodynamic stability, and reduce postoperative nausea and vomiting in a variety of surgical populations, including abdominal surgery. Meta-analyses have also demonstrated improved recovery of bowel function associated with intraoperative dexmedetomidine use.
Despite these findings, existing studies have largely focused on intraoperative administration, and there is limited evidence regarding the potential benefits of continued dexmedetomidine infusion in the postoperative period, particularly in patients undergoing bowel surgery. This represents an important knowledge gap, as the immediate postoperative phase is when opioid exposure is highest and recovery trajectories are established. Dexmedetomidine's opioid-sparing effects, favorable sedation profile, and potential to facilitate gastrointestinal recovery suggest it may be well suited for postoperative use in this population.
The PODEX study was designed to evaluate whether a continued postoperative dexmedetomidine infusion improves recovery outcomes following laparoscopic-assisted bowel surgery. The study is a single-center, randomized, double-blind, placebo-controlled clinical trial conducted at Mount Sinai Hospital. Participants are adults undergoing elective or semi-elective laparoscopic-assisted bowel surgery who receive standardized perioperative care. All participants receive dexmedetomidine intraoperatively as part of routine anesthetic management, ensuring that the study specifically evaluates the incremental benefit of postoperative continuation of dexmedetomidine rather than its initiation during surgery.
Following surgery, participants are randomized to receive either dexmedetomidine or a matched placebo administered as a continuous intravenous infusion for up to 48 hours using a continuous ambulatory delivery device. The selected infusion rate reflects prior evidence demonstrating efficacy for analgesia and gastrointestinal recovery while minimizing risks of hypotension, bradycardia, and excessive sedation, making it appropriate for use on a surgical ward rather than an intensive care setting.
The study emphasizes patient-centered recovery using validated instruments rather than relying solely on traditional clinical endpoints. Recovery is assessed using the Quality of Recovery-15 (QoR-15) questionnaire, a multidimensional, patient-reported outcome measure that captures physical comfort, pain, emotional well-being, psychological support, and functional independence. Additional assessments evaluate pain intensity, opioid consumption, gastrointestinal recovery, length of hospital stay, and postoperative complications. Together, these measures provide a comprehensive evaluation of both subjective and objective recovery following surgery.
Dexmedetomidine is associated with known, dose-dependent cardiovascular effects, including bradycardia and hypotension, and as such, safety monitoring is an integral component of the study design. Participants are monitored for hemodynamic events, sedation, and other adverse events throughout the infusion period and follow-up. A structured monitoring protocol and predefined criteria for intervention or discontinuation are used to mitigate risk and ensure participant safety.
The statistical approach follows an intention-to-treat framework. The study is powered to detect a clinically meaningful difference in quality of recovery based on established thresholds for the QoR-15 instrument. Secondary analyses explore differences in opioid exposure, pain trajectories, gastrointestinal recovery, and hospital length of stay, providing insight into potential mechanisms underlying any observed improvement in recovery.
By focusing on postoperative continuation of dexmedetomidine in a well-defined surgical population, this study aims to generate high-quality evidence addressing an unmet need in perioperative care. If effective, postoperative dexmedetomidine infusion could represent a scalable, low-cost strategy to enhance recovery, reduce opioid-related morbidity, and improve patient experience after bowel surgery. The findings may inform future perioperative analgesia protocols and contribute to the development of evidence-based guidelines for postoperative pain management in abdominal surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Cardiac impairment defined as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postoperative dexmedetomidine infusion 100 mcg/mL at a rate of 0.15 mcg/kg/h for a total of 48 hours via a continuous ambulatory delivery device (CADD) pump
Drug: Dexmedetomidine infusion
Postoperative matched placebo of 0.9% saline infusion for a total of 48 hours via a continuous ambulatory delivery device (CADD) pump
Other: Postoperative matched placebo of 0.9% saline infusion
Postoperative dexmedetomidine infusion 400 mcg in 100 mL at a rate of 0.15 mcg/kg/h for a total of 48 hours via a continuous ambulatory delivery device (CADD) pump
Arm Description: Postoperative matched placebo of 0.9% saline infusion for a total of 48 hours via a continuous ambulatory delivery device (CADD) pump
Quality of recovery: QoR-15 scores at 48 hours postoperatively.
The primary outcome of the study is the Quality of Recovery (QoR-15) score at 48 hours following surgery. The QoR-15 is a validated 15-item questionnaire that assesses four key domains of postoperative recovery: physical comfort, emotional state, physical independence, and psychological support. In this questionnaire, values range from 0 to 150 where higher scores indicate better recovery and lower scores indicate poorer recovery. The decision to use QoR-15 as the primary outcome was informed in part based on patient feedback, as QoR-15 captures the patient's overall recovery experience rather than narrowly focusing on pain or opioid use. This provides a more patient-centered measure of analgesia effectiveness that aligns with modern perioperative analgesia research.
Time frame: Up to 7 days post-operatively
Quality of recovery: QoR-15 scores at 24, 72 hours, and 7 days postoperatively.
The secondary outcome of the study is the Quality of Recovery (QoR-15) score at 24, 72 hours and, 7 days following surgery. The QoR-15 is a validated 15-item questionnaire that assesses four key domains of postoperative recovery: physical comfort, emotional state, physical independence, and psychological support. In this questionnaire, values range from 0 to 150 where higher scores indicate better recovery and lower scores indicate poorer recovery. These time points capture early, intermediate, and short-term recovery trajectories, allowing assessment of the sustained clinical impact of the study intervention beyond pain intensity alone.
Time frame: Up to 7 days post-operatively
2. Opioid consumption (measured in morphine milligram equivalents) at 24, 48, and 72 hours, and 7 days postoperatively
Time frame: Up to 7 days post-operatively
3. Pain management: Pain scores assessed by Numeric Rating Scale (NRS) at 24, 48, 72 hours, and 7 days, postoperatively.
Pain intensity will be assessed using the Numeric Rating Scale (NRS) at 24, 48, 72 hours, and 7 days postoperatively to evaluate the effectiveness of the study intervention on acute and short-term postoperative pain control. The Numeric Rating Scale (NRS) is a validated, widely used patient-reported measure of pain intensity consisting of an 11-point scale ranging from 0 to 10, where 0 represents "no pain" and 10 represents "worst imaginable pain." Higher scores indicate worse pain. These time points capture early and evolving postoperative pain trajectories and allow assessment of both immediate and sustained analgesic effects.
Time frame: Up to 7 days post-operatively
Postoperative complications: Incidence of nausea, vomiting, ileus, pruritus, and sedation.
Time frame: Up to 7 days post-operatively
Time to return of bowel function, defined as: time to first flatus, time to first bowel movement, time to tolerating oral regular or soft diet.
Time frame: Up to 7 days post-operatively
Hospital length of stay (LOS): Duration of postoperative hospitalization in days.
Time frame: Up to 7 days post-operatively
Hemodynamic complications: incidences of systolic blood pressure <90 mmHg, incidences of heart rate <50 beats per minute throughout the intervention period, including 24 hours following completion of the intervention.
Time frame: Up to 7 days post-operatively
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Jul 2027, 12 months later.
Of 28 phase 3 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 83. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine